Dare Bioscience, Inc.

Welcome to the conference call hosted by DARE Bioscience to review the company's second quarter 2025 financial results and to provide a business update. This call is being recorded. My name is Jericho and I will be your operator today. With us today from DARE are Sabrina Martucci-Johnson, President and Chief Executive Officer, and Marty Herring-Layton, Chief Accounting Officer. Ms. Herring-Layton, please proceed.

Good afternoon and welcome to the DARE Bioscience Financial Results and Business Update Call for the quarter ended June 30, 2025. Today we will review our financial results, provide updates on our clinical pipeline, and discuss the continued execution of our expanded business strategy. That strategy includes a dual path approach, commercializing proprietary formulations through 503 compounding while pursuing FDA approval. and advancing select solutions as branded consumer health products that do not require a prescription. In all cases, our goal is to bring innovative women's health solutions to market as efficiently and quickly as possible. I would like to remind you that today's discussion will include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical facts should be considered forward-looking statements. Actual results or events could differ materially from those anticipated or implied by these statements due to known and unknown risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements are qualified in their entirety by the cautionary statements and the company's SEC filings, including our Form 10-Q for the quarter ended June 30th, 2025, which was filed today, and our Form 10-K for the year ended December 31, 2024. I would also like to point out that the content of this call includes time-sensitive information that is current only as of today, August 14, 2025. DARE undertakes no obligation to update any forward-looking statements to reflect new information or developments after this call, except as required by law. I will now turn it over to Sabrina.

Thank you, Marty, and thank you to everyone joining us today. We are already at an inflection point. The second quarter of 2025 reflects the continued acceleration of our dual path strategy as we focus on closing the gap in women's health between promising science and real solutions, generating near-term commercial revenue while advancing long-term innovation in women's health. We remain on track to support the commercial availability of Dare to Play Sildenafil Cream through a 503 outsourcing facility in the fourth quarter of this year. This anticipated launch represents a major milestone, not just for DARE, but for the field of women's sexual health, where innovation has historically lagged behind other therapeutic areas. At the same time, we continue to advance our differentiated clinical pipeline, which includes primarily grant-funded programs targeting areas of significant unmet need. including contraception, HPV, and preterm birth. We believe this dual path approach enables us to unlock value efficiently by leveraging non-dilutive capital and a disciplined investment strategy. Let me walk you through several highlights from my cross-sell portfolio. First, Dare to Place with NFL Cream, a near-term revenue opportunity. We remain on track to support a fourth quarter 2025 launch.